Latest Antibody dependent enhancement Stories
By re-engineering a tiny chain of amino acids in one type of dengue virus, Ralph Baric and Aravinda de Silva discover a new path toward solving the dengue vaccine dilemma.
One of the most vexing challenges in the battle against dengue virus, a mosquito-borne virus responsible for 50-100 million infections every year, is that getting infected once can put people at greater risk for a more severe infection down the road.
Dengue disease can be deadly.
A team of researchers has identified a cellular protein that acts as a receptor for Ebola virus and Marburg virus. Furthermore, the team showed that an antibody, which binds to the receptor protein, is able to block infection by both viruses.
Finding has major implications for efforts to develop a first-ever vaccine against the dangerous infectious disorder.
Research published this week in PLoS Medicine challenges the dogma of the antibody-dependent enhancement model (ADE) for the development of dengue hemorrhagic fever (DHF).
CAMBRIDGE, Mass., Sept. 24 /PRNewswire/ -- Peptimmune, Inc.
Number of cases of tropical disease continue to grow along US border, worldwide.
Some virusesâ€™ ability to exploit the human bodyâ€™s own defenses to increase their replication may be both a blessing and curse, according to the findings of a study conducted by researchers at the Johns Hopkins Bloomberg School of Public Health.
A monoclonal antibody that can effectively treat mice infected with West Nile virus has an intriguing secret: Contrary to scientists' expectations, it does not block the virus's ability to attach to host cells. Instead, the antibody somehow stops the infectious process at a later point.
- A volcanic mudflow.